Current status and prospects of antiplatelet therapy in percutaneous coronary intervention in Japan: Focus on adenosine diphosphate receptor inhibitors

Journal of Cardiology

Volumn 58, Issue 1, 2011, Pages 6-17

  Ogawa, Hisao ^a   Hokimoto, Seiji ^a   Kaikita, Koichi ^a   Yamamoto, Koichiro ^a   Chitose, Tadasuke ^a   Ono, Takamichi ^a   Tsujita, Kenichi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Adenosine diphosphate; Cardiovascular disease; Drug therapy; Platelet inhibitors; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 2C19; FLUINDOSTATIN; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRASUGREL; PROTON PUMP INHIBITOR; SIMVASTATIN; TICAGRELOR; TICLOPIDINE;

ACUTE CORONARY SYNDROME; AGRANULOCYTOSIS; ANGIOPLASTY; ANTICOAGULANT THERAPY; APLASTIC ANEMIA; ARTICLE; ASIAN; BLEEDING; BRAIN ISCHEMIA; CAUCASIAN; CLINICAL PROTOCOL; CORONARY STENT; DIABETIC PATIENT; DRUG ABSORPTION; DRUG ACTIVATION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG INHIBITION; DRUG INTERACTION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; EMBOLISM; ENZYME ACTIVITY; GAIN OF FUNCTION MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEPATITIS; HOMOZYGOTE; HUMAN; INTERMITTENT CLAUDICATION; JAPAN; LABORATORY TEST; LIVER TOXICITY; LOADING DRUG DOSE; NEUTROPENIA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OBSTRUCTIVE JAUNDICE; PATIENT CODING; PATIENT COMPLIANCE; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; RECURRENT DISEASE; RISK REDUCTION; STENT THROMBOSIS; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNITED STATES; UNSTABLE ANGINA PECTORIS; VASCULAR SURGERY; WILD TYPE;

EID: 79959704369     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2011.03.002     Document Type: Review

References (77)

1. Angiolillo D.J., Bhatt D.L., Gurbel P.A., Jennings L.K. Advances in antiplatelet therapy: agents in clinical development. Am J Cardiol 2009, 103:40A-51A.
2. Ogawa H., Kojima S. Modern state of acute myocardial infarction in the interventional era: observational case-control study-Japanese acute coronary syndrome study (JACSS). J Cardiol 2009, 54:1-9.
3. Angiolillo D.J. Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol 2009, 103:27A-34A.
4. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
5. Angiolillo D.J., Ueno M., Goto S. Basic principles of platelet biology and clinical implications. Circ J 2010, 74:597-607.
6. Murugappa S., Kunapuli S.P. The role of ADP receptors in platelet function. Front Biosci 2006, 11:1977-1986.
7. Foster C.J., Prosser D.M., Agans J.M., Zhai Y., Smith M.D., Lachowicz J.E., Zhang F.L., Gustafson E., Monsma F.J., Wiekowski M.T., Abbondanzo S.J., Cook D.N., Bayne M.L., Lira S.A., Chintala M.S. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001, 107:1591-1598.
8. Hollopeter G., Jantzen H.M., Vincent D., Li G., England L., Ramakrishnan V., Yang R.B., Nurden P., Nurden A., Julius D., Conley P.B. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001, 409:202-207.
9. Paciaroni M., Bogousslavsky J. Clopidogrel for cerebrovascular prevention. Cerebrovasc Dis 1999, 9:253-260.
10. Raju N.C., Eikelboom J.W., Hirsh J. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nat Clin Pract Cardiovasc Med 2008, 5:766-780.
11. Sanofi-aventis. Ticlopidine (Panaldine®): Japan prescribing information; 2010.
12. Leon M.B., Baim D.S., Popma J.J., Gordon P.C., Cutlip D.E., Ho K.K., Giambartolomei A., Diver D.J., Lasorda D.M., Williams D.O., Pocock S.J., Kuntz R.E. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting, Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998, 339:1665-1671.
13. Schomig A., Neumann F.J., Kastrati A., Schuhlen H., Blasini R., Hadamitzky M., Walter H., Zitzmann-Roth E.M., Richardt G., Alt E., Schmitt C., Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996, 334:1084-1089.
14. Hass W.K., Easton J.D., Adams H.P., Pryse-Phillips W., Molony B.A., Anderson S., Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients, Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989, 321:501-507.
15. Gent M., Blakely J.A., Easton J.D., Ellis D.J., Hachinski V.C., Harbison J.W., Panak E., Roberts R.S., Sicurella J., Turpie A.G. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989, 1:1215-1220.
16. Bergqvist D., Almgren B., Dickinson J.P. Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: results from the Swedish Ticlopidine Multicentre Study (STIMS). Eur J Vasc Endovasc Surg 1995, 10:69-76.
17. Sanofi-aventis. Clopidogrel (Plavix®): Japan prescribing information; 2010.
18. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996, 348:1329-1339.
19. Chen Z.M., Jiang L.X., Chen Y.P., Xie J.X., Pan H.C., Peto R., Collins R., Liu L.S. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005, 366:1607-1621. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group.
20. Sabatine M.S., Cannon C.P., Gibson C.M., Lopez-Sendon J.L., Montalescot G., Theroux P., Claeys M.J., Cools F., Hill K.A., Skene A.M., McCabe C.H., Braunwald E Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005, 352:1179-1189. CLARITY-TIMI 28 Investigators.
21. Bertrand M.E., Rupprecht H.J., Urban P., Gershlick A.H. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000, 102:624-629.
22. Taniuchi M., Kurz H.I., Lasala J.M. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation 2001, 104:539-543.
23. Muller C., Buttner H.J., Petersen J., Roskamm H. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000, 101:590-593.
24. Uchiyama S., Fukuuchi Y., Yamaguchi T. The safety and efficacy of clopidogrel versus ticlopidine in Japanese stroke patients: combined results of two Phase III, multicenter, randomized clinical trials. J Neurol 2009, 256:888-897.
25. Anderson J.L., Adams C.D., Antman E.M., Bridges C.R., Califf R.M., Casey D.E., Chavey W.E., Fesmire F.M., Hochman J.S., Levin T.N., Lincoff A.M., Peterson E.D., Theroux P., Wenger N.K., Wright R.S., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007, 116:e148-e304.
26. Smith S.C., Feldman T.E., Hirshfeld J.W., Jacobs A.K., Kern M.J., King S.B., Morrison D.A., O'Neill W.W., Schaff H.V., Whitlow P.L., Williams D.O., Antman E.M., Smith S.C., Adams C.D., Anderson J.L., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006, 47:e1-e121.
27. The Japanese Circulation Society. Guidelines for management of anticoagulant and antiplatelet therapy in cardiovascular disease; 2009. Circulation Journal 2009; supplement [web only:]. http://www.j-circ.or.jp/guideline/index.htm.
28. Hagihara K., Kazui M., Kurihara A., Yoshiike M., Honda K., Okazaki O., Farid N.A., Ikeda T. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos 2009, 37:2145-2152.
29. Savcic M., Hauert J., Bachmann F., Wyld P.J., Geudelin B., Cariou R. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost 1999, 25(Suppl. 2):15-19.
30. Angiolillo D.J., Suryadevara S., Capranzano P., Zenni M.Z., Guzman L.A., Bass T.A. Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists. Catheter Cardiovasc Interv 2009, 73:1-14.
31. Gorog D.A., Sweeny J.M., Fuster V. Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact. Nat Rev Cardiol 2009, 6:365-373.
32. Kuliczkowski W., Witkowski A., Polonski L., Watala C., Filipiak K., Budaj A., Golanski J., Sitkiewicz D., Pregowski J., Gorski J., Zembala M., Opolski G., Huber K., Arnesen H., Kristensen S.D., De Caterina R. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2009, 30:426-435.
33. Hoshino K., Horiuchi H., Tada T., Tazaki J., Nishi E., Kawato M., Ikeda T., Yamamoto H., Akao M., Furukawa Y., Shizuta S., Toma M., Tamura T., Saito N., Doi T., et al. Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary intervention. Circ J 2009, 73:336-342.
34. Sweeny J.M., Gorog D.A., Fuster V. Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nat Rev Cardiol 2009, 6:273-282.
35. Desta Z., Zhao X., Shin J.G., Flockhart D.A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002, 41:913-958.
36. Simon T., Verstuyft C., Mary-Krause M., Quteineh L., Drouet E., Meneveau N., Steg P.G., Ferrières J., Danchin N., Becquemont L. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009, 360:363-375. French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators.
37. Collet J.P., Hulot J.S., Pena A., Villard E., Esteve J.B., Silvain J., Payot L., Brugier D., Cayla G., Beygui F., Bensimon G., Funck-Brentano C., Montalescot G. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009, 373:309-317.
38. Mega J.L., Close S.L., Wiviott S.D., Shen L., Hockett R.D., Brandt J.T., Walker J.R., Antman E.M., Macias W., Braunwald E., Sabatine M.S. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360:354-362.
39. Pare G., Mehta S.R., Yusuf S., Anand S.S., Connolly S.J., Hirsh J., Simonsen K., Bhatt D.L., Fox K.A., Eikelboom J.W. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010, 363:1704-1714.
40. Jinnai T., Horiuchi H., Makiyama T., Tazaki J., Tada T., Akao M., Ono K., Hoshino K., Naruse Y., Takahashi K., Watanabe H., Kita T., Kimura T. Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan. Circ J 2009, 73:1498-1503.
41. Yamamoto K., Hokimoto S., Chitose T., Morita K., Ono T., Kaikita K., Tsujita K., Abe T., Deguchi M., Miyagawa H., Saruwatari J., Sumida H., Sugiyama S., Nakagawa K., Ogawa H. Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy. J Cardiol 2011, 57:194-201.
42. Holmes D.R., Dehmer G.J., Kaul S., Leifer D., O'Gara P.T., Stein C.M ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA "Boxed Warning": A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2010, 56:321-341.
43. van de Graaff E., Steinhubl S.R. Variable interindividual responses to antiplatelet therapies - do they exist, can we measure them, and are they clinically relevant. Heart Drug 2001, 1:35-43.
44. Bhindi R., Ormerod O., Newton J., Banning A.P., Testa L. Interaction between statins and clopidogrel: is there anything clinically relevant. QJM 2008, 101:915-925.
45. Ng F.H., Chan P., Kwanching C.P., Loo C.K., Cheung T.K., Wong S.Y., Kng C., Ng K.M., Lai S.T., Wong B.C. Management and outcome of peptic ulcers or erosions in patients receiving a combination of aspirin plus clopidogrel. J Gastroenterol 2008, 43:679-686.
46. Ng F.H., Lam K.F., Wong S.Y., Chang C.M., Lau Y.K., Yuen W.C., Chu W.M., Wong B.C. Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy. Digestion 2008, 77:173-177.
47. Ho P.M., Maddox T.M., Wang L., Fihn S.D., Jesse R.L., Peterson E.D., Rumsfeld J.S. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009, 301:937-944.
48. Potter B.J., Le Lorier J. Letter by Potter and Le Lorier regarding article, "Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome" Circulation 2010, 122:e414. author reply e5.
49. Rassen J.A., Choudhry N.K., Avorn J., Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009, 120:2322-2329.
50. O'Donoghue M.L., Braunwald E., Antman E.M., Murphy S.A., Bates E.R., Rozenman Y., Michelson A.D., Hautvast R.W., Ver Lee P.N., Close S.L., Shen L., Mega J.L., Sabatine M.S., Wiviott S.D. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009, 374:989-997.
51. Bliden K.P., DiChiara J., Tantry U.S., Bassi A.K., Chaganti S.K., Gurbel P.A. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate. J Am Coll Cardiol 2007, 49:657-666.
52. Valgimigli M., Campo G., de Cesare N., Vranckx P., Hamon M., Angiolillo D.J., Sabatè M., Ferrari F., Furgieri A., Tumscitz C., Repetto A., Colangelo S., Meliga E., Kubbajeh M., Parrinello G., et al. Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R), Rationale for the study and protocol design. Cardiovasc Drugs Ther 2008, 22:313-320.
53. Angiolillo D.J., Shoemaker S.B., Desai B., Yuan H., Charlton R.K., Bernardo E., Zenni M.M., Guzman L.A., Bass T.A., Costa M.A. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007, 115:708-716.
54. Kim J.Y., Lee K., Shin M., Ahn M., Choe H., Yoo B.S., Yoon J., Choe K.H., Lee S.H. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circ J 2007, 71:1867-1872.
55. Angiolillo D.J., Capranzano P., Goto S., Aslam M., Desai B., Charlton R.K., Suzuki Y., Box L.C., Shoemaker S.B., Zenni M.M., Guzman L.A., Bass T.A. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J 2008, 29:2202-2211.
56. Campo G., Valgimigli M., Gemmati D., Percoco G., Catozzi L., Frangione A., Federici F., Ferrari F., Tebaldi M., Luccarelli S., Parrinello G., Ferrari R. Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study. J Am Coll Cardiol 2007, 50:1132-1137.
57. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., Neumann F.J., Ardissino D., De Servi S., Murphy S.A., Riesmeyer J., Weerakkody G., Gibson C.M., Antman E.M. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-2015. TRITON-TIMI 38 Investigators.
58. Ogawa H., Kojima S. Clinical evidence for Japanese population based on prospective studies-Linking clinical trials and clinical practice. J Cardiol 2009, 54:171-182.
59. Eli Lilly and Co./Daiichi Sankyo Inc. Prasugrel (Effient®): US prescribing information; 2010.
60. Brandt J.T., Payne C.D., Wiviott S.D., Weerakkody G., Farid N.A., Small D.S., Jakubowski J.A., Naganuma H., Winters K.J. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007, 153:66.e9-66.e16.
61. Jernberg T., Payne C.D., Winters K.J., Darstein C., Brandt J.T., Jakubowski J.A., Naganuma H., Siegbahn A., Wallentin L. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006, 27:1166-1173.
62. Varenhorst C., James S., Erlinge D., Brandt J.T., Braun O.O., Man M., Siegbahn A., Walker J., Wallentin L., Winters K.J., Close S.L. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 2009, 30:1744-1752.
63. Mega J.L., Close S.L., Wiviott S.D., Shen L., Hockett R.D., Brandt J.T., Walker J.R., Antman E.M., Macias W.L., Braunwald E., Sabatine M.S. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009, 119:2553-2560.
64. Koo M.H., Nawarskas J.J., Frishman W.H. Prasugrel: a new antiplatelet drug for the prevention and treatment of cardiovascular disease. Cardiol Rev 2008, 16:314-318.
65. Antman E.M., Wiviott S.D., Murphy S.A., Voitk J., Hasin Y., Widimsky P., Chandna H., Macias W., McCabe C.H., Braunwald E. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008, 51:2028-2033.
66. Wiviott S.D., Braunwald E., McCabe C.H., Horvath I., Keltai M., Herrman J.P., Van de Werf F., Downey W.E., Scirica B.M., Murphy S.A., Antman E.M. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008, 371:1353-1363. TRITON-TIMI 38 Investigators.
67. Montalescot G., Wiviott S.D., Braunwald E., Murphy S.A., Gibson C.M., McCabe C.H., Antman E.M. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009, 373:723-731. TRITON-TIMI 38 investigators.
68. Smith P.K., Despotis G.J., Goodnough L.T., Levy J.H., Poston R.S., Short M.A., Weerakkody G.J., LeNars L.A. Abstract 10881: mortality benefit with prasugrel in TRITON - TIMI 38 coronary artery bypass grafting (CABG) cohort: risk adjusted retrospective data analysis. Circulation 2010, 122:A10881.
69. Small D.S., Payne C.D., Kothare P., Yuen E., Natanegara F., Teng Loh M., Jakubowski J.A., Richard Lachno D., Li Y.G., Winters K.J., Farid N.A., Ni L., Salazar D.E., Tomlin M., Kelly R. Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30mg and clopidogrel 300mg in healthy Chinese and white volunteers: an open-label trial. Clin Ther 2010, 32:365-379.
70. Small D.S., Kothare P., Yuen E., Lachno D.R., Li Y.G., Winters K.J., Farid N.A., Ni L., Jakubowski J.A., Salazar D.E., Thieu V.T., Payne C.D. The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects. Eur J Clin Pharmacol 2010, 66:127-135.
71. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., Horrow J., Husted S., James S., Katus H., Mahaffey K.W., Scirica B.M., Skene A., Steg P.G., Storey R.F., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361:1045-1057.
72. Hollmuller I., Stadlmann S., Graziadei I., Vogel W. Clinico-histopathological characteristics of clopidogrel-induced hepatic injury: case report and review of literature. Eur J Gastroenterol Hepatol 2006, 18:931-934.
73. Ng J.A., Goldberg N., Tafreshi M.J. Clopidogrel-induced hepatotoxicity and fever. Pharmacotherapy 2006, 26:1023-1026.
74. Skurnik Y.D., Tcherniak A., Edlan K., Sthoeger Z. Ticlopidine-induced cholestatic hepatitis. Ann Pharmacother 2003, 37:371-375.
75. Fukushima K., Kobayashi Y., Okuno T., Nakamura Y., Sakakibara M., Nakayama T., Kuroda N., Miyazaki A., Shimizu Y., Komuro I. Incidence of side-effects of ticlopidine after sirolimus-eluting stent implantation. Circ J 2007, 71:617-619.
76. Goto S., Toda E. Antiplatelet therapy after coronary intervention in Asia and Japan: the Asian perspective of antiplatelet intervention. Hamostaseologie 2009, 29:321-325.
77. Hirata K., Takagi H., Yamamoto M., Matsumoto T., Nishiya T., Mori K., Shimizu S., Masumoto H., Okutani Y. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J 2008, 8:29-33.